Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine discusses the close intersection between metabolic disorders and cardiovascular disease, covering the basic science and pathophysiology of disease and the latest research in pharmacological approaches and translational therapeutic options. This book is a valuable resource for the vascular and endocrinology clinical and research communities in need of knowledge and potential outcomes.
The global increase in the prevalence of cardiometabolic disorders, and the introduction of therapeutic options for treating metabolic disease that also lower cardiovascular risk, is bringing endocrinologists and cardiologists together in a shared clinical experience.
- Discusses the intersection between metabolic disorders and cardiovascular diseases
- Provides a comprehensive understanding of the relevant pathophysiology of diseases as a basis for the evidence-based management of cardiometabolic disorders
- Offers a comprehensive reference, ranging from basic science and pathophysiology to clinical diagnostics and management
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
Illustrationen
Approx. 100 illustrations (50 in full color)
Dateigröße
ISBN-13
978-0-323-98318-1 (9780323983181)
Schweitzer Klassifikation
Part 1. Basic science and pathophysiology1. Obesity and insulin resistance2. Diabetes and macrovascular disease: epidemiology and cardiovascular risk assessment3. Hypertension4. Lipid metabolism: role in atherogenesis5. Renal disease and cardiorenal interactions6. NAFLD/NASH and cardiovascular risk7. Heart failure8. Prothrombosis: association with cardiometabolic disease9. Inflammation, metabolism and cardiovascular disease10. Classic endocrine disorders: association with vascular diseasePart 2. Clinical evaluation, lifestyle measures and therapeutic options11. Non-pharmacological strategies in the prevention and management of cardiometabolic disease12. Obesity: pharmacological approaches to prevention and management13. Diabetes: evolution of multifactorial vascular risk reduction14. Diabetes CVOTS: design, interpretation and future directions15. Novel glucose-lowering drugs: a new era of cardioprotection and renoprotection16: Hypertension: pharmacological and surgical management17. PCSK-9 inhibitors and other novel lipid-modifying drugs18. Recent therapeutic developments in heart failure19. Antiplatelet agents20. Progress in anticoagulant therapy21. Invasive treatment of atherosclerotic cardiovascular disease: today and tomorrow22. Cardiometabolic medicine in practice: role of cardiologists vs endocrinologists and the need for a new clinical specialty
